Scholar Rock Holding Corp (SRRK) Stock AnalysisSRRKStock AnalysisScholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scholar Rock Holding Corp (SRRK) appears to be a good buy right now due to its current price of $57.80, which is below the analyst price target range of $63 to $76. The stock has shown a strong year-to-date change of +35.05% and a one-year change of +74.52%, indicating robust upward momentum. Additionally, the RSI is at 58.61, suggesting the stock is neither overbought nor oversold, which is favorable for new investors. However, the main risk is the ongoing net losses, with the latest reported net income showing a loss of $108.76 million for Q2 2026, which could impact future performance if not addressed.

4 analysts cover SRRK: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.